Corporate News

• 
  Beilu Pharma's Iopamidol Injection passed the Consistency Evaluation of Generic Drugs!

  2022/02/18

  Recently, Beilu Pharma received the “Approval Notice for Supplementary Drug Application” for two specifications of Iopamidol Injection issued by the NMPA (Notice No.: 2022B00641, 2022B00642). Follow...

  VIEW_MORE
• 
  New Specifications of Repaglinide Tablets from Beilu Pharma Were Deemed to Have Passed the Generic Drugs Quality and Efficacy Consistency Evaluation

  2021/12/20

  Now, our company received the Notification of Approval of Supplementary Application for Repaglinide Tablets issued by the State Medical Products Administration (Notification No. : 2021 B04618). After ...

  VIEW_MORE
• 
  109 Million! Subsidiary Hichi Pharmaceutical Completed a New Round of Financing to Help Increase Profitability

  2021/12/02

  To further promote the development of the company's main business and enhance the company's competitiveness, Zhejiang Hichi Pharmaceutical Co., Ltd., its holding subsidiary, launched a new ...

  VIEW_MORE
• 
  Beilu Pharmaceutical Jiuwei Zhenxin granule was selected into the Quotscience and Technology Innovation Chinaquot New Drug Achievement

  2021/11/30

  Recently, Beilu Pharmaceutical Jiuwei Zhenxin Granules were successfully selected into the "Science and Innovation China" New Drug Achievement Case Library of the China Association for Scien...

  VIEW_MORE
• 
  Beilu was awarded the “Top 100 Small and Medium-sized Private Enterprises in Beijing” and “Top 100 Private Enterprises in Beijing for Social Responsibility”

  2021/09/17

  Recently, the Beijing Municipal Federation of Industry and Commerce and the Beijing Branch of China Construction Bank jointly held the“2021 Beijing Top 100 Private Enterprises Press Conference”.

  VIEW_MORE
• 
  Beilu's Gadopentetate Dimeglumine Injection Passed the Quality and Efficacy of Generic Drugs Consistency Evaluation

  2021/07/27

  Recently, our company received the“Drug Supplementary Application Approval Notice”(Notice Number: 2021B02267, 2021B02268) for two specifications of Gadopentetate Dimeglumine Injection.

  VIEW_MORE
• 
  Beilu Pharma's Iohexol Injection Won the Bid in the Fifth round of National Centralized Drug Procurement

  2021/06/24

  Beilu Pharma participated in the fifth round of national centralized drug procurement organized by the National Organization for Centralized Drug Procurement and Use of the Joint Procurement Office.

  VIEW_MORE